Sclerosis News and Research

RSS

Biogen Idec 2011 total revenues increase 7% to $5.0 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its full year and fourth quarter 2011 results.

1 Feb 2012

Gilenya prevents and reverses symptoms of ventricular hypertrophy

A drug used to treat multiple sclerosis may also be effective at preventing and reversing the leading cause of heart attack, a new study has found.

30 Jan 2012

Muscle endurance tests can detect abnormalities in early stages of MS

Multiple sclerosis (MS), a neurodegenerative disease, causes periodic attacks of neurologic symptoms such as limb weakness and mobility defects. And while MS patients' walking abilities and muscle strength are examined on a regular basis, doctors have yet to determine when the lower limb muscles begin to deteriorate.

27 Jan 2012

Multiple sclerosis drug Gilenya under investigation by FDA and EMA

The US Food and Drugs Administration (FDA) and European Medicines Agency (EMA) are looking at the pros and cons of using Gilenya (fingolimod) in treating the neurological autoimmune disease Multiple Sclerosis (MS).

23 Jan 2012

FDA allows marketing of Stratify JCV Antibody ELISA test for PML

Today, the U.S. Food and Drug Administration allowed marketing of the first test to help determine the risk for a rare brain infection called progressive multifocal leukoencephalopathy (PML) in people using the drug Tysabri (natalizumab) to treat multiple sclerosis (MS) or Crohn's disease.

21 Jan 2012

FDA approves product label change for Biogen Idec's TYSABRI to treat MS

Today Biogen Idec and Elan Corporation, plc announced that the U.S. Food and Drug Administration (FDA) has approved a product label change for TYSABRI that will help enable individual benefit risk assessment for patients with multiple sclerosis.

21 Jan 2012

MSC-mediated RNAi transfer holds promise for Huntington's disease

A team of researchers at the UC Davis Institute for Regenerative Cures has developed a technique for using stem cells to deliver therapy that specifically targets the genetic abnormality found in Huntington's disease, a hereditary brain disorder that causes progressive uncontrolled movements, dementia and death.

20 Jan 2012

Memory retraining using mSMT increases cerebral activation in MS patients

Neuroscientists at Kessler Foundation have documented increased cerebral activation in patients with multiple sclerosis (MS) following memory retraining using the modified Story Memory Technique (mSMT).

18 Jan 2012

Converted umbilical cord stem cells hold hope for spinal cord injuries, multiple sclerosis

For the first time ever, stem cells from umbilical cords have been converted into other types of cells, which may eventually lead to new treatment options for spinal cord injuries and multiple sclerosis, among other nervous system diseases.

18 Jan 2012

Neuronal energy deficits may contribute to amyotrophic lateral sclerosis

Turning off a protein that helps cells balance energy increases animal mobility and reduces the death of nerve cells that control movement in animal models of amyotrophic lateral sclerosis (ALS), according to a study in the January 18 issue of The Journal of Neuroscience. The findings may one day guide new directions for the treatment of the progressive neurodegenerative disorder, for which there is currently no cure.

18 Jan 2012

Vitamin D provides no relief from chronic obstructive pulmonary disease

Earlier studies have suggested that up to three quarters of people with severe chronic obstructive pulmonary disease, or COPD, are deficient in the vitamin. So it was thought that giving them extra vitamin D might help prevent exacerbations in symptoms or trips to the hospital because of shortness of breath or mucus in the airways. Belgian researchers have refuted this claim.

17 Jan 2012

AAN neurologist receives prestigious award at Palatucci Advocacy Leadership Forum

The American Academy of Neurology(AAN) has named neurologist Constantine Moschonas, MD, of Scottsdale, Ariz., as the AAN Donald M. Palatucci Advocacy Leadership Forum Advocate of the Year. Moschonas received his award at the Palatucci Advocacy Leadership Forum on January 14, 2012, in Austin, Texas, for his outstanding work in raising awareness about brain diseases such as Alzheimer's disease, stroke, autism, Parkinson's disease and multiple sclerosis.

17 Jan 2012

Angioplasty improves quality of life in MS patients

Although using angioplasty to treat multiple sclerosis (MS) is highly controversial, sufferers often insist it helps - in some cases dramatically, such as allowing them to walk without a cane. Patients with less severe MS also reported additional quality of life improvements, such as being able to talk more clearly, after having treatment to open blocked blood vessels in the chest and neck, according to research being presented at the 24th annual International Symposium on Endovascular Therapy.

17 Jan 2012

Virtual reality technology will advance rehabilitation research for cognitive and physical disabilities

Kessler Foundation and the University of Southern California (USC) Institute for Creative Technologies will collaborate on clinical research projects applying virtual reality technology to cognitive and motor rehabilitation research.

11 Jan 2012

Now cannabis mouth spray to help ‘pot’ addicts quit

To help smokers quit there are nicotine patches and heroin users have methadone. However till date cannabis users have little choice except stop abruptly to quit. Cannabis withdrawal symptoms include severe insomnia, pot cravings and mood swings. “Although these are not life-threatening, they are significant enough to cause marked distress and lead people to go back to using the drug,” said lead researcher Jan Copeland.

10 Jan 2012

'Where is my Memory? Cognitive Changes in MS' teleconference to be held on Jan. 24

John DeLuca, PhD, VP for Research at Kessler Foundation, will conduct a teleconference, "Where is my Memory? Cognitive Changes in MS," on Tues., January 24, 6:30-7:30 pm. Dr. DeLuca is well known for his neuropsychology research in cognition and multiple sclerosis and is a licensed psychologist in New Jersey and New York.

10 Jan 2012

Questcor reports record vial shipments of Acthar in fourth quarter 2011

In preparation for meetings starting Monday, January 9 with investors and an investor presentation scheduled for 10:00 a.m. Thursday, January 12 at the J. P. Morgan Healthcare Conference, Questcor Pharmaceuticals, Inc. today announced preliminary operating metrics for the fourth quarter 2011.

7 Jan 2012

New Zealand life science and health IT companies to showcase their products in San Francisco

New Zealand is well known for its wines and stunning scenery, but the country is also a great source of innovation in the life sciences. A delegation of New Zealand life sciences companies who have reached key stages in their development are joining the throngs of international therapeutics, medical device and health IT companies in San Francisco, January 9 - 12 to showcase their products and capabilities to potential corporate partners and investors.

7 Jan 2012

Study provides hope for stimulating remyelination in MS patients

Scientists at Joslin Diabetes Center, Harvard University, and the University of Cambridge have found that the age-related impairment of the body's ability to replace protective myelin sheaths, which normally surround nerve fibers and allow them to send signals properly, may be reversible, offering new hope that therapeutic strategies aimed at restoring efficient regeneration can be effective in the central nervous system throughout life.

7 Jan 2012

Age-associated decline of remyelination process may be reversible

New research highlights the possibility of reversing ageing in the central nervous system for multiple sclerosis (MS) patients. The study is published today, 06 January, in the journal Cell Stem Cell.

7 Jan 2012